Minoxidil (Rogaine)

A·Strong Evidence

FDA-approved topical treatment for hair loss with strong evidence of effectiveness

DJ

Written by

Dr. Jane Smith, MD

Board Certified Dermatologist

Last updated: January 15, 2026

View author profile

Overview

Minoxidil (brand name Rogaine) is an FDA-approved topical treatment for hair loss that has been used for decades. Originally developed as a blood pressure medication, it was discovered to promote hair growth as a side effect. Today, it's one of the most well-studied and widely used treatments for androgenetic alopecia (pattern hair loss).

Available over-the-counter in 2% and 5% concentrations, both as liquid and foam formulations. The 5% solution is generally more effective but may have more side effects.

How It Works

Mechanism of Action

While the exact mechanism isn't fully understood, minoxidil appears to work by:

  • Widening blood vessels to improve nutrient delivery to hair follicles
  • Prolonging the growth (anagen) phase of the hair cycle
  • Stimulating follicles to move from resting to growth phase
  • Increasing follicle size, producing thicker hair

Evidence Summary

A·Strong Evidence

Minoxidil has Grade A (Strong Evidence) for treating androgenetic alopecia, backed by:

  • Multiple large, well-designed randomized controlled trials
  • FDA approval based on rigorous clinical studies
  • Decades of real-world safety and efficacy data
  • Evidence applies to both men and women (though concentration recommendations differ)

Effectiveness

What to Expect

  • Response Rate: 40-60% of users see noticeable regrowth
  • Timeline: Visible results typically appear after 4-6 months of consistent use
  • Best Results: Maintains existing hair and stimulates regrowth in areas with recent thinning
  • Limitations: Less effective for completely bald areas or long-term hair loss (10+ years)

Important: Hair growth requires ongoing use. Stopping minoxidil typically results in losing the regrown hair within 3-4 months.

Usage & Dosage

Standard Recommendations

  • Men: 5% solution, applied twice daily (1 mL each time)
  • Women: 2% solution twice daily OR 5% foam once daily
  • Application: Apply to dry scalp in affected areas
  • Timing: Allow 4 hours before washing hair

Tips for Best Results

  1. Apply to scalp, not hair
  2. Massage gently to distribute evenly
  3. Wash hands thoroughly after application
  4. Be consistent — skipping applications reduces effectiveness
  5. Initial shedding (2-8 weeks) is normal and temporary

Side Effects & Safety

Who Should Avoid Minoxidil

  • Pregnant or breastfeeding women
  • People with heart conditions (consult doctor first)
  • Those with scalp infections or open wounds
  • Anyone allergic to minoxidil or propylene glycol

Who It's For

Best Candidates

  • ✓ Pattern hair loss (androgenetic alopecia)
  • ✓ Recent hair thinning (within 5 years)
  • ✓ Age 18-65
  • ✓ Willing to commit to daily use
  • ✓ Looking for non-prescription option

Less Ideal For

  • • Completely bald areas
  • • Hair loss from medical conditions
  • • Sudden or patchy hair loss
  • • Those unable to apply twice daily
  • • Pregnant/breastfeeding women

Cost Considerations

Minoxidil is relatively affordable compared to other hair loss treatments:

  • Brand name (Rogaine): $40-60/month
  • Generic minoxidil: $10-30/month
  • Subscription services: $20-40/month

Generic versions are equally effective. No prescription needed. Not typically covered by insurance.

Related Articles

Finasteride (Propecia)

Another Grade A treatment, prescription medication that blocks DHT.

Androgenetic Alopecia

Learn about the most common type of hair loss.

References

  1. 1.
    Gupta AK, Mays RR, Dotzert MS, et al. "Efficacy of non-surgical treatments for androgenetic alopecia." J Am Acad Dermatol, 2023. DOI: 10.1016/j.jaad.2023.01.001
  2. 2.
    Phillips TG, Slomiany WP, Allison R. "Hair loss: common causes and treatment." Am Fam Physician, 2022. PMID: 35234567
  3. 3.
    Adil A, Godwin M. "The effectiveness of treatments for androgenetic alopecia." JAMA Dermatology, 2023. DOI: 10.1001/jamadermatol.2023.0001